A Phase 4 interventional study of Permethrin 5% and Synthomycine 5% in Inflammation of the Eyelids, sponsored by Barzilai Medical Center. Status unknown at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-30.
Sponsored by Barzilai Medical Center · Phase 4, Interventional, and Treatment
The study aims to investigate the effect of Permethrin 5% treatment on Signs and symptoms of Demodex-blepharitis in comparison to Synthomycine 5% and Fucithalmic (fusidic acid 1%) .
3 arms study. 75 patient total, 25 patients in each group.
Group A (study group) patients will apply facially Permethrin 5% every night for 3 months.
Group B patients will apply on the eyelids Fusidic acid 1% every night for 3 months.
Group C patients will apply on the eyelids Synthomycine 5% every night for 3 months
Follow up Evaluation will be made after one week, one month, two months, three months, 4 months and half a year.
Exclusion Criteria:
Contains permethrin 5% w/w (equivalent to 50 mg/g), formaldehyde solution 0.278% w/w and butylated hydroxytoluene (E321) 0.02% w/w.
Drug: Permethrin 5%
Contains chloramphenicol 5%.
Drug: Synthomycine 5%
Contains 1% w/w fusidic acid anhydrous (as the hemihydrates) and 0.011% w/w.
Drug: Fusidic Acid 1% M/R Eye Drops
Facial skin application once a night for 3 months.
Eye ointment, eyelids and eyelashes application (chloramphenicol), once a night for 3 months.
viscous eye drops application once a night for 3 months.
Decrease in demodex infestation in group A (permethrin 5%).
significant decrease in demodex infestation in comparison to group B and C.
Time frame: 2 months
Improvement in symptoms and complaints in group A.
OSDI Questionnaires that describe the severity of the ocular surface disease condition are filled in each visit.
Time frame: 2 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Barzilai Medical Center